| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 06/08/2006 | CA2586735A1 Antitumor combinations containing a vegf inhibitor and 5fu or one of its derivatives |
| 06/08/2006 | CA2584136A1 Enhancer of the effect of adrenocorticoid, comprising gum arabic |
| 06/07/2006 | EP1666883A1 Diagnostic and monitoring methods for bone loss |
| 06/07/2006 | EP1666606A1 Method for detecting regulatory effect on controlling synoviolin activity |
| 06/07/2006 | EP1666600A1 Methods for enhancing the efficacy of cancer therapy |
| 06/07/2006 | EP1666594A2 Polypeptide, nucleic acid encoding it, and their use for the diagnosis of cancer |
| 06/07/2006 | EP1666592A1 A fungal immuromodulatory protein produced by microorganisme and uses there of |
| 06/07/2006 | EP1666591A1 Cytokine that induces apoptosis |
| 06/07/2006 | EP1666587A1 Cyclic lipopeptide acylase |
| 06/07/2006 | EP1666585A1 Macroencapsulated secretory cells |
| 06/07/2006 | EP1666499A2 Novel inhibitors of vascular endothelial growth factor activity, their uses and processes for their production |
| 06/07/2006 | EP1666498A2 Soluble CTLA4 molecules, compositions comprising said molecules and uses thereof |
| 06/07/2006 | EP1666497A2 Polypeptide, nucleic acid encoding it, and their use for the diagnosis of cancer |
| 06/07/2006 | EP1666496A1 Interferon-beta composite |
| 06/07/2006 | EP1666493A1 Secreted and transmembrane polypeptides and nucleic acids ancoding the same |
| 06/07/2006 | EP1666492A1 Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| 06/07/2006 | EP1666491A1 Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| 06/07/2006 | EP1666487A1 Purification of hbv antigens for use in vaccines |
| 06/07/2006 | EP1666068A1 Remedy for eye diseases accompanied by optic nerve injuries |
| 06/07/2006 | EP1666062A2 Therapeutic applications for the anti-T-BAM (CD40-L) monoclonal antibody 5c8 |
| 06/07/2006 | EP1666058A2 Method of and compositions for immunization with the pseudomonas V antigen |
| 06/07/2006 | EP1666055A1 Method for treating oncological, virulent and somatic diseases, method for controlling treatment efficiency, pharmaceutical agents and composition for carrying out said treatment |
| 06/07/2006 | EP1666054A1 Method for administering insulinotropic peptides |
| 06/07/2006 | EP1666053A1 Methods and compositions for stimulating neurite growth using compounds with affinity for fkbp12 in combination with neurotrophic factors |
| 06/07/2006 | EP1666052A1 Uses of agonists and antagonists to modulate activity of TNF-related molecules |
| 06/07/2006 | EP1666048A2 Method for producing insulin from a natural source and insulin |
| 06/07/2006 | EP1666047A1 Pharmaceutical compositions comprising nitric oxide-releasing pyrrolidones |
| 06/07/2006 | EP1666037A2 Compositions for stimulating neurite growth |
| 06/07/2006 | EP1666028A1 Dry powder compositions having improved dispersivity |
| 06/07/2006 | EP1666026A2 Non-aqueous single phase biocompatible viscous vehicles and methods for preparing the same |
| 06/07/2006 | EP1664798A2 Non-peptide agonists and antagonists of adrenomedullin and gastrin releasing peptide |
| 06/07/2006 | EP1664332A2 Kinase and phosphatase assays |
| 06/07/2006 | EP1664326A2 The use of plp with peg-rmetase in vivo for enhanced efficacy |
| 06/07/2006 | EP1664302A1 Flagellar genetic sequences of brucella being of therapeutic and diagnostic use |
| 06/07/2006 | EP1664294A2 Regulation of cardiac contractility and heart failure propensity |
| 06/07/2006 | EP1664293A2 Plasminogen activators having reduced lysine binding capacity |
| 06/07/2006 | EP1664290A2 Diagnostics and therapeutics for diseases associated with kallikrein 11 (klk11) |
| 06/07/2006 | EP1664275A2 In vivo synthesis of connective tissues |
| 06/07/2006 | EP1664272A2 Targeting endothelium for tissue-specific delivery of agents |
| 06/07/2006 | EP1664270A1 Chimeric antigens for breaking host tolerance to foreign antigens |
| 06/07/2006 | EP1664269A2 Alpha-keto carbonyl calpain inhibitors |
| 06/07/2006 | EP1664127A1 Synthetic polysaccharide antigens for immunological intervention in disease |
| 06/07/2006 | EP1664109A1 Purification of glucagon-like peptides |
| 06/07/2006 | EP1664108A1 Separation of polypeptides comprising a racemized amino acid |
| 06/07/2006 | EP1664107A2 Synthetic antimicrobial polypeptides |
| 06/07/2006 | EP1664105A2 Vegf-induced genes and their therapeutic use |
| 06/07/2006 | EP1664104A1 A protein involved in carcinoma |
| 06/07/2006 | EP1664096A1 Antimicrobial polypeptides |
| 06/07/2006 | EP1664095A2 Antimicrobial polypeptides |
| 06/07/2006 | EP1664093A1 New antitumoral compounds |
| 06/07/2006 | EP1664092A1 Macrocyclic inhibitors of hepatitis c virus ns3 serine protease |
| 06/07/2006 | EP1664091A1 Inhibitors of serine proteases, particularly hcv ns3-ns4a protease |
| 06/07/2006 | EP1664090A2 Novel peptidomimetic ns3-serine protease inhibitors of hepatitis c virus |
| 06/07/2006 | EP1664088A2 Hemiasterlin derivatives and uses thereof |
| 06/07/2006 | EP1664081A2 Novel proteins and nucleic acids encoding same |
| 06/07/2006 | EP1664075A2 Methods for diagnosing and treatment of conditions that alter phosphate transport in mammals |
| 06/07/2006 | EP1664074A2 Polymorphic nucleoside compounds |
| 06/07/2006 | EP1663317A1 Epas1 gene transfer to improve cell therapy |
| 06/07/2006 | EP1663305A1 A method selecting an immunotherapeutic preparation |
| 06/07/2006 | EP1663300A1 Inhibitors of pace4 for the treatment of arthritis |
| 06/07/2006 | EP1663299A2 Methods for preventing neurological events |
| 06/07/2006 | EP1663298A2 Use of proline specific endoproteases to hydrolyse peptides and proteins |
| 06/07/2006 | EP1663296A1 Liquid human growth hormone formulation containing polyethylene glycol |
| 06/07/2006 | EP1663295A2 Stable formulations of peptides |
| 06/07/2006 | EP1663294A1 Treatment of fibrotic disease |
| 06/07/2006 | EP1663293A2 Vege-cor vege-d materials and methods for stimulation of neural stem cells |
| 06/07/2006 | EP1663292A1 Formulation of albumin-free erythropoietin |
| 06/07/2006 | EP1663291A2 Recombinant lubricin molecules and uses thereof |
| 06/07/2006 | EP1663290A2 Modulators of p-selectin glycoprotein ligand 1 |
| 06/07/2006 | EP1663289A2 Methods for treating or ameliorating ghrelin-associated diseases and disorders |
| 06/07/2006 | EP1663287A1 Use of modified cyclosporins for the treatment of hcv disorders |
| 06/07/2006 | EP1663286A2 In vivo modulation of neuronal transport |
| 06/07/2006 | EP1663285A2 Use of peptidic conjugates for preparing compositions for alopecia preventive and curative treatment |
| 06/07/2006 | EP1663284A1 Compositions and methods for treatment of psoriasis |
| 06/07/2006 | EP1663283A1 Glutamine for use in treating injury |
| 06/07/2006 | EP1663282A1 Oral compositions for the stimulation of gastric acid secretion comprising pentagastrin |
| 06/07/2006 | EP1663281A2 Poly-pegylated protease inhibitors |
| 06/07/2006 | EP1663280A1 Method to enhance hematopoiesis |
| 06/07/2006 | EP1663279A2 Modified protease inhibitors |
| 06/07/2006 | EP1663278A2 Epo mimetic peptides and fusion proteins |
| 06/07/2006 | EP1663277A2 Somatogenic therapy using a 20kda placental variant of growth hormone |
| 06/07/2006 | EP1663276A2 Compounds that modulate neuronal growth and their uses |
| 06/07/2006 | EP1663275A2 Stationary phases and a purification process using the stationary phases |
| 06/07/2006 | EP1663262A2 Bowman-birk inhibitor compositions for treatment of muscular atrophy and degenerative muscle disease |
| 06/07/2006 | EP1663256A1 Carbohydrate composition and its use for the preparation of a medicament for treating or preventing pulmonary inflammation or acute respiration distress syndrome |
| 06/07/2006 | EP1663236A1 Combination comprising n-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-¬1,3,4-oxadiazol-2-yl| phenyl)pyridine-3-sulphonamide and an lhrh analogue and/or a biphosphonate |
| 06/07/2006 | EP1663208A1 Use of telmisartan for the prevention of vascular headache |
| 06/07/2006 | EP1663188A2 Treatment of disorders of the nervous system |
| 06/07/2006 | EP1663181A2 Protein binding compounds |
| 06/07/2006 | EP1663177A1 Topical preparations comprising a hydrophilic carrier and a silicone matrix |
| 06/07/2006 | EP1663146A2 Method for production of bioresorbable microparticles microparticles thus obtained and use thereof |
| 06/07/2006 | EP1663118A2 Peptide-based conditioners and colorants for hair, skin, and nails |
| 06/07/2006 | EP1663111A2 Delivery of physiologixal agents with in-situ gels comprising anionic polysaccharides |
| 06/07/2006 | EP1663109A2 Ultrasonic concentration of drug delivery capsules |
| 06/07/2006 | EP1662903A1 Food composition |
| 06/07/2006 | EP1662879A2 Indirect delivery of growth factors into the central nervous system |
| 06/07/2006 | EP1662874A2 Co-administration of polysaccharide with a chemotherapeutic agent for the treatment of cancer |
| 06/07/2006 | EP1662862A1 Receptor |
| 06/07/2006 | EP1434787A4 Lp mammalian proteins; related reagents |
| 06/07/2006 | EP1425029A4 Peptidomimetics of biologically active metallopeptides |